The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with San
On the face of it, the battle between Amgen and Sanofi/Regeneron being heard in the US Supreme Court is a mundane biopharma contest over rights and royalties on PCSK9 inhi
Daiichi Sankyo has succeeded in a bid to convince the US Patent and Trademark Office (PTO) to take another look at a patent held by Seagen that was previously deemed to ha
AstraZeneca followed a long and arduous road to bring its CTLA4 inhibitor Imjudo to market, and will now have to defend its new product from a patent infringement complaint brought by Brist
It looks like Astellas has been unsuccessful in its attempt to block Pfizer's generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexis
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas